EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Induced pluripotent stem cell (iPSC)-derived CAR-macrophages: new kids on the block

Fucai Zhu, Zhongfa Chen, Yan Yu, Lanlan Rao, Guifang Lin, Jing Deng, Qiuhua Yu

Experimental Hematology · 2026

DOI: 10.1016/j.exphem.2026.105384 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Experimental Hematology, 2026. Verfasst von Fucai Zhu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi Maternal and Child Health Hospital, Donghu District, Nanchang City, Jiangxi Province, China. Electronic address: zhufucai20250101@outlook.com. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Macrophages. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 179 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Remarkable outcomes of chimeric antigen receptor (CAR)-T cell therapy in treating hematologic malignancies have inspired parallel efforts to harness the potential of other immune cell types for CAR-based immunotherapy. These efforts aim to overcome the existing limitations of CAR-T cell therapy. In recent years, CAR-macrophages (CAR-MACs) have shown astonishing efficacy in cancer treatment, leading to the approval of several CAR-MAC products for clinical trials. The lack of T-cell receptor (TCR) expression allows them to be used in allogeneic settings and as off-the-shelf products. Within the tumor microenvironment (TME), they can suppress tumor growth via multimodal mechanisms, including CAR-dependent and CAR-independent activities. They can also remodel the TME and prime other immune cells to enhance antitumor responses. Despite these merits, obtaining a sufficient number of MACs from traditional sources is challenging or is subject to regulatory hurdles. This review explores induced pluripotent stem cells (iPSCs) as an emerging source for generating iPSC-derived CAR-MACs (CAR-iMACs). In this regard, we began with an overview of MACs and their conventional sources and discussed the advantages of iPSCs over these traditional sources. After that, the technical procedures for generating iPSCs and differentiating them into functional CAR-iMACs were comprehensively discussed. Finally, we explored the preclinical and clinical advances in CAR-iMAC therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Induced Pluripotent Stem CellsReceptors, Chimeric AntigenImmunotherapy, AdoptiveMacrophagesHematologic NeoplasmsHumansAnimalsTumor Microenvironment

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Jiangxi Maternal and Child Health Hospital, Donghu District, Nanchang City, Jiangxi Province, China. Electronic address: zhufucai20250101@outlook.com.
  • Jiangxi Maternal and Child Health Hospital, Donghu District, Nanchang City, Jiangxi Province, China.
  • First Affiliated Hospital of Gannan Medical University, Zhanggong District, Ganzhou City, Jiangxi Province, China.

Zitieren

APA

Zhu, F., Chen, Z., Yu, Y., Rao, L., Lin, G., Deng, J., & Yu, Q. (2026). Induced pluripotent stem cell (iPSC)-derived CAR-macrophages: new kids on the block. Experimental Hematology. https://doi.org/10.1016/j.exphem.2026.105384

Vancouver

Zhu F, Chen Z, Yu Y, Rao L, Lin G, Deng J, et al. Induced pluripotent stem cell (iPSC)-derived CAR-macrophages: new kids on the block. Experimental Hematology. 2026. doi:10.1016/j.exphem.2026.105384

BibTeX
@article{Zhu2026,
  author = {Zhu, Fucai and Chen, Zhongfa and Yu, Yan and Rao, Lanlan and Lin, Guifang and Deng, Jing and Yu, Qiuhua},
  title = {Induced pluripotent stem cell (iPSC)-derived CAR-macrophages: new kids on the block},
  journal = {Experimental Hematology},
  year = {2026},
  doi = {10.1016/j.exphem.2026.105384}
}
Kostenlos starten →